All In Biotech

Drug Trial Radar · NCT07336940

Study of ENV-294 in Healthy Adults and in Adults With Moderate-to-Severe Atopic Dermatitis

A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Escalation, and Food Effect Study of ENV-294 in Healthy Adult Participants With a Phase 1b Extension in Adults With Moderate-To-Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Apr 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

9

Actual

Start

Sep 10, 2025

Primary completion

Jan 13, 2026

Study completion Jan 13, 2026

Sponsor

Lead sponsor
Enveda TherapeuticsIndustry
Sponsor type
Industry
First posted
Jan 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn about the safety and tolerability of ENV-294 in adults with moderate to severe atopic dermatitis. It may also learn about the changes ENV-294 may have on the severity of atopic dermatitis symptoms. The main questions it will answer are: * Is ENV-294 safe and well tolerated in adults with moderate to severe atopic dermatitis? * Is there an impact on the severity of atopic dermatitis symptoms when participants take ENV-294? Researchers will review the atopic dermatitis present at the beginning of the study against the atopic dermatitis present at the end of the study. Participants will: * Take drug ENV-294 once every day for 28 days * Visit the clinic weekly for 4 weeks for checkups and tests * Keep a diary of their symptoms and when they took their study drug ENV-294

Conditions

  • Atopic Dermatitis (AD)

Interventions

  • ENV-294 CapsuleDrug

    ENV-294 formulated as 200mg capsules for oral administration will be used for this study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the safety and tolerability of ENV-294 when administered to adult participants with moderate-to-severe atopic dermatitis.Time frame: From enrollment through treatment and the final study visit at approximately day 42.
  2. Incidence of abnormalities in clinical chemistry parameters as a measure of safety and tolerability of ENV-294.Time frame: Baseline through end of study at approximately Day 42.
  3. To assess the safety and tolerability of ENV-294 when administered to adult participants with moderate-to-severe atopic dermatitisTime frame: From first dose through treatment and the final study visit at approximately day 42.
  4. Incidence of clinically significant changes in systolic blood pressure (mmHg) as a measure of safety and tolerability of ENV-294.Time frame: From first dose through treatment and the final study visit at approximately day 42.
  5. Incidence of clinically significant changes in heart rate (beats per minute) measured by 12-lead ECG as a measure of safety and tolerability of ENV-294.Time frame: Baseline through treatment and the final study visit at approximately day 42.
  6. Incidence of abnormalities in hematology parameters as a measure of safety and tolerability of ENV-294.Time frame: Baseline through the end of the study at approximately Day 42.
  7. Incidence of abnormalities in coagulation parameters as a measure of safety and tolerability of ENV-294.Time frame: Baseline through the end of the study at approximately Day 42.
  8. Incidence of abnormalities in urinalysis parameters as a measure of safety and tolerability of ENV-294.Time frame: Baseline through the end of the study at approximately Day 42.
  9. Incidence of clinically significant changes in diastolic blood pressure (mmHg) as a measure of safety and tolerability of ENV-294.Time frame: Baseline through treatment and the final study visit (approximately Day 42).
  10. Incidence of clinically significant changes in heart rate as a measure of safety and tolerability of ENV-294.Time frame: Baseline through treatment and the final study visit (approximately Day 42).
  11. Incidence of clinically significant changes in respiratory rate as a measure of safety and tolerability of ENV-294.Time frame: Baseline through treatment and the final study visit (approximately Day 42).
  12. Incidence of clinically significant changes in body temperature as a measure of safety and tolerability of ENV-294.Time frame: Baseline through treatment and the final study visit (approximately Day 42).
  13. Incidence of clinically significant changes in RR interval (milliseconds) measured by 12-lead ECG as a measure of safety and tolerability of ENV-294.Time frame: Baseline through treatment and the final study visit (approximately Day 42).
  14. Incidence of clinically significant changes in PR interval (milliseconds) measured by 12-lead ECG as a measure of safety and tolerability of ENV-294.Time frame: Baseline through the end of the study at approximately Day 42.
  15. Incidence of clinically significant changes in QRS duration (milliseconds) measured by 12-lead ECG as a measure of safety and tolerability of ENV-294.Time frame: Baseline through treatment and the final study visit (approximately Day 42).
  16. Incidence of clinically significant changes in QT interval (milliseconds) measured by 12-lead ECG as a measure of safety and tolerability of ENV-294.Time frame: Baseline through treatment and the final study visit (approximately Day 42).
  17. Incidence of clinically significant changes in QTc Bazett (milliseconds) measured by 12-lead ECG as a measure of safety and tolerability of ENV-294.Time frame: Baseline through treatment and the final study visit (approximately Day 42)
  18. Incidence of clinically significant changes in QTc Fridericia (milliseconds) measured by 12-lead ECG as a measure of safety and tolerability of ENV-294.Time frame: From enrollment through treatment and the final study visit (approximately Day 42)

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Center for Dermatology Clinical Research, Inc.

    Fremont, California

  • Skin Sciences, PLLC

    Louisville, Kentucky

  • J & S Studies

    College Station, Texas

  • Texas Dermatology and Laser Specialists

    San Antonio, Texas

  • Virginia Dermatology & Skin Cancer Center

    Norfolk, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.